Xycota Biosciences

Target the repair pathway. Not the trip. Preclinical neuroscience: a low-dose psilocybin capsule designed to be taken at home. First question: mild PTSD.

[Xycota Biosciences @xycota]

4/4 Preclinical and investigational. Not approved by any regulatory authority. Forward-looking statements involve risks and uncertainties; actual results may differ. Not an offer to buy or sell securities. #MMA #BrainHealth

[Xycota Biosciences @xycota]

1/4 From the MMA cage to pro sports and military service, repetitive head impacts (mTBI) and trauma frequently overlap, disrupting sleep, mood, and cortical BDNF/TrkB signaling in rat models.

[Xycota Biosciences @xycota]

3/4 Observed in rats, not people. Whether a sub-perceptual capsule (XYCO-02) engages TrkB in humans with mild PTSD is untested.
Join the movement: https://t.co/N1bWCKpxhD

[Xycota Biosciences @xycota]

4/4 Preclinical and investigational. Not approved by any regulatory authority. Forward-looking statements involve risks and uncertainties; actual results may differ. Not an offer to buy or sell securities. #Neuroscience #PTSDResearch

[Xycota Biosciences @xycota]

1/4 That happened in a rat model of Fragile X (Ascone et al., 2026). Whether it translates to adults with mild PTSD is the open question our proposed trial with KGK Science is built to test.

[Xycota Biosciences @xycota]

3/4 Open Question 3: In the proposed Health Canada trial, serum BDNF in blood is a supporting readout alongside CAPS-5, not a surrogate endpoint.
https://t.co/vrDaOw0s29

[Xycota Biosciences @xycota]

UFC Hall of Famer @bisping joins @xycota CSO Dr. Marvin Hausman (@BioAdaptivesInc) on head impact, PTSD & psilocybin research: https://t.co/ropgspvAR3

Preclinical/rat data; unapproved. Deal signed, not closed. Paid MyndSystem ambassador.
#UFC #PTSD #mTBI
$BDPT

[Xycota Biosciences @xycota]

4/4 Preclinical and investigational. Not approved by any regulatory authority. Forward-looking statements involve risks and uncertainties; actual results may differ. Not an offer to buy or sell securities. #PTSDResearch #Veterans

[Xycota Biosciences @xycota]

1/4 For veterans, first responders, and everyday adults living with PTSD, chronic stress physically prunes synaptic connections in the prefrontal cortex, as studied in preclinical rat models of BDNF/TrkB signaling.

[Xycota Biosciences @xycota]

3/4 Observed in rats, not people. Whether a sub-perceptual capsule (XYCO-02) helps adults with mild PTSD is what we aim to test.
Join the movement: https://t.co/N1bWCKpxhD

[Xycota Biosciences @xycota]

This Veterans Day, honoring service means confronting what follows too many home.

29% of Iraq/Afghanistan vets face PTSD, yet only 27% screening positive get care. Trauma is biology, not weakness.

Free, no-login PTSD Hub: https://t.co/2ugPNbuWaZ
#VeteransDay #PTSD
$BDPT

[Xycota Biosciences @xycota]

4/4 Preclinical and investigational. Not approved by any regulatory authority. #Neuroscience #Biotech

[Xycota Biosciences @xycota]

1/4 Two switches. In a 2026 rat study (Ascone et al., Neuropsychopharmacology, DOI: 10.1038/s41386-026-02361-x), repeated low-dose oral psilocybin (0.1 mg/kg p.o.) rescued object-recognition memory in male Fmr1 rats.

[Xycota Biosciences @xycota]

3/4 Observed in rats. Not people. A Fragile X rat model is not human PTSD, and whether a sub-perceptual oral capsule engages TrkB in humans has not yet been tested.
https://t.co/Y8oe8JDXGB

[Xycota Biosciences @xycota]

Target the repair pathway. Not the trip.

How Xycota Biosciences is testing whether the TrkB-BDNF synaptic repair pathway (Ascone et al., 2026) can be engaged by a sub-perceptual 1.5 mg oral capsule (XYCO-02) at home: https://t.co/Uc4U4foxtx

Preclinical/investigational.

[Xycota Biosciences @xycota]

Target the repair pathway. Not the trip.

In the 2026 Fragile X rat study (Ascone et al.), memory rescue persisted under 5-HT2A blockade and disappeared under TrkB blockade. Next question: mild PTSD in humans (XYCO-02). https://t.co/1ucscqsMYW

Preclinical; not approved.